Studying Kawasaki disease with a serious immune complication in children
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at Kawasaki disease that gets complicated by a serious immune reaction called macrophage activation syndrome (MAS). It aims to better understand and treat this complication in children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 4 weeks old and under 18 years old when diagnosed with Kawasaki disease.
- Kawasaki disease must be diagnosed by a doctor using the 2024 American Heart Association guidelines.
- The complication called macrophage activation syndrome (MAS) must be diagnosed within 30 days of the start of Kawasaki disease.
- The child must not have a primary (genetic) form of HLH, a related immune condition.
- You must give permission (informed consent) for your child to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain genes (called HERVs) in children with new inflammatory conditions like Kawasaki disease, COVID-19, or other infections. It aims to learn more about how these genes might be involved in the body's response to illness.
This study looks at children with Kawasaki disease, a condition that causes inflammation in blood vessels. The goal is to learn more about how it affects kids in Europe and North India.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
This study uses heart imaging to better understand Kawasaki disease. It may help doctors assess heart health in affected children and teenagers.
This study tests whether anakinra, a medicine that calms inflammation, is just as good as the standard treatment for Kawasaki disease in children. The goal is to reduce fever and prevent heart problems.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.